Thermo Fisher Scientific Inc. (TMO)

Over the past six months, Thermo Fisher Scientific's stock price has experienced a decline. The shares have underperformed the S&P 500 Index and have been trading below their 50-day and 200-day moving averages since early February, indicating a bearish trend. Despite this, the company's stock saw a more than 6% increase on January 30, 2025, following the release of its Q4 2024 results. Recent company activities impacting the stock include the declaration of a quarterly dividend on May 21, 2025, and the unveiling of next-generation mass spectrometers at ASMS 2025 on June 2, 2025. In April 2025, the company announced investments to enhance U.S. innovation and support customer manufacturing. Additionally, in June 2025, Thermo Fisher secured a US$94.5 million contract for the Navy's next-generation dosimetry system and partnered with RoosterBio in May 2025 to increase the availability of cell and exosome therapies.

Demand for some of Thermo Fisher Scientific's products exhibits seasonality, particularly for allergy and flu tests. The company's overall demand is influenced by the capital spending policies of its diverse customer base. Thermo Fisher Scientific's demand planning processes incorporate methods to account for trends, seasonality, and product life cycle changes. Potential interest rate cuts could improve the funding environment and positively impact demand.

Thermo Fisher Scientific is a global leader in life science and clinical research, operating within the Healthcare sector and the Laboratory Equipment, Biotechnology, Pharmaceutical, and Medical Diagnostics & Research industries. The company offers a comprehensive portfolio of analytical instruments, life sciences solutions, specialty diagnostics, and laboratory, pharmaceutical, and biotechnology services. Its major products include laboratory supplies, equipment, and instruments, clinical and diagnostics tools, chromatography and mass spectrometry devices, chemicals, cell culture materials, protein and cell analysis tools, and molecular biology and nucleic acid analysis products. Beyond products, Thermo Fisher Scientific is a significant provider of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services.

Thermo Fisher Scientific has a worldwide presence with over 60 locations across 25 countries for its pharma services. The company has expanded its footprint in North America, Europe, and Asia-Pacific. It also maintains a considerable commercial and manufacturing presence in India. Geographically, its net sales are distributed with North America accounting for 53.1%, Europe 25.1%, Asia/Pacific 18.4%, and other regions 3.5%.

Thermo Fisher Scientific maintains a strong brand reputation as a "world leader in serving science." The company has received accolades as an employer of choice, including recognition in the Sodexo Employer of the Region 2022 Competition and Employer of the Year. Forbes recognized Thermo Fisher Scientific in its 2025 lists, including Global 2000, Net Zero Leaders, and Most Trusted Companies in America. The company's commitment to innovation, research and development, and strategic acquisitions have solidified its market position. Thermo Fisher Scientific played a crucial role in supporting the COVID-19 pandemic response.

Thermo Fisher Scientific's ownership structure is primarily institutional, with approximately 51.76% to 89.89% of the company's stock held by institutional investors. Key institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors hold a smaller portion, around 0.1% of shares, while insiders own approximately 0.12%.